Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Down on Analyst Downgrade

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares gapped down prior to trading on Wednesday after DZ Bank downgraded the stock from a strong-buy rating to a strong sell rating. The stock had previously closed at $14.40, but opened at $13.32. Bayer Aktiengesellschaft shares last traded at $13.47, with a volume of 210,773 shares trading hands.

Other equities research analysts also recently issued reports about the company. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Down 3.5%

The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14. The firm has a fifty day moving average price of $12.17 and a 200 day moving average price of $9.62. The firm has a market capitalization of $50.34 billion, a price-to-earnings ratio of -142.32, a PEG ratio of 4.76 and a beta of 0.68.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.